Analytical Data
-
基因名
EGFR vIII
-
简介
The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR vIII Protein, Human (HEK293, His-Avi) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with N-Avi, N-His labeled tag.
- Application
-
别名
ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2
-
种属
Human
-
表达系统
HEK293
-
标签
N-Avi;N-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
NP_001333870
-
表达区间
L25-S378
-
蛋白长度
Partial
-
分子量
68-80 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EGFRvIII is a mutant form of the epidermal growth factor receptor (EGFR) that is frequently overexpressed in various malignancies, particularly in glioblastoma, a highly aggressive brain tumor. This mutation results from a deletion of exons 2-7 in the EGFR gene, leading to a constitutively activated receptor that drives tumorigenesis through enhanced cell proliferation, survival, and invasiveness. The unique expression profile of EGFRvIII, as compared to the wild-type receptor, makes it an attractive target for cancer immunotherapy and therapeutic interventions. Researchers have been exploring the potential of recombinant EGFRvIII proteins as vaccine candidates to elicit a robust immune response against tumor cells expressing this mutant protein. These studies aim to harness the body's immune system to specifically recognize and destroy cancer cells while sparing normal tissues, thus improving treatment outcomes. Furthermore, the development of EGFRvIII-targeting therapies, including monoclonal antibodies and CAR-T cells, holds promise for creating personalized cancer treatment strategies. The comprehensive understanding of EGFRvIII biology and its role in tumor progression is crucial for advancing therapeutic approaches that could provide a significant clinical benefit for patients with EGFRvIII-positive tumors.
